Measurement System of Jaw Movement for Diagnosing Mandibular Disorders

Politecnico di Milano (sola presentazione orale

Cancer-associated oxidoreductase ERO1-α drives the production of VEGF via oxidative protein folding and regulating the mRNA level

Background: Endoplasmic reticulum disulfide oxidase 1-alpha (ERO1-alpha) is an oxidase that exists in the endoplasmic reticulum and has a role in the formation of disulfide bonds of secreted proteins and cell-surface proteins. Recently, we reported that ERO1-alpha is present in high levels in various types of tumours, and that ERO1-alpha is a novel factor of poor prognosis. However, how ERO1-alpha affects a tumour in vivo and why patients who have a tumour with a high expression level of ERO1-alpha have a poor prognosis are still unknown. Therefore, to clarify the mechanism, we investigated the effect of ERO1-alpha on a tumour from the point of view of angiogenesis. Methods: The effect of ERO1-alpha on tumour growth and angiogenesis was analysed by using non-obese diabetic-severe combined immunodeficient mice. The production of vascular endothelial growth factor (VEGF) in MDA-MB-231 cells with ERO1-alpha-overexpression or with ERO1-alpha knockdown was measured. The role of ERO1-alpha on VEGF expression was investigated. In triple-negative breast cancer cases, the relationship between expression of ERO1-alpha and angiogenesis was analysed. Results: We found that the expression of ERO1-alpha promoted tumour growth in a mouse study and angiogenesis. The effects of ERO1-alpha on angiogenesis were mediated via oxidative protein folding of VEGF and enhancement of VEGF mRNA expression by using MDA-MB-231. In triple-negative breast cancer cases, the expression of ERO1-alpha related to the number of the blood vessel. Furthermore, we found that ERO1-alpha was a poor prognosis factor in triple-negative breast cancer. Conclusions: Our study has established a novel link between expression of ERO1-alpha and secretion of VEGF, providing new evidence for the effectiveness of ERO1-alpha-targeted therapy in patients with ERO1-alpha-expressed cancer

Significant effect of polymorphisms in CYP2D6 on response to tamoxifen therapy for breast cancer: A prospective multicenter study

10.1158/1078-0432.CCR-16-1779Clinical Cancer Research2382019-2026CCRE

A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study

10.1371/journal.pone.0201606PLoS ONE138e0201606POLN